Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 3, 1996, Pages 441-446

  Simon, B ^a   Ravelli, G P ^b   Goffin, H ^c  

^a Kreiskrankenhaus Schwetzingen ^*  (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ECR Eucam Clinical Research Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CITOGEL; GASTROGEL; PLACEBO; SUCRALFATE; SUCRATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; SUCRALFATE;

EID: 0029967216     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-0673.1996.00441.x     Document Type: Article

References (17)

1. Gallup, Gallup Survey on Heartburn Across America, Princeton, NJ: The Gallup Organization, 24 March 1988.
2. Hardy JG, Hooper G, Ravelli GP, Steed KP, Wilding IR. A comparison of the gastric retention of a sucralfate gel and a sucralfate suspension. Eur J Pharmacol Biopharmacol 1993; 39 (2): 70-4.
3. Savary M, Miller G. Der Oesophagus. Lehrbuch und Endoskopischer Atlas. Solothurn: Verlag Gassmann AG, 1977: 155.
4. Nyren O, Adami HO, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986; 314: 339-13.
5. Mead GM, Morris A, Webster GK, Langman MJS. Uses of barium meal examination in dyspeptic patients under SO. BMJ 1977; 1: 1460-1.
6. Lindberg G. On the similarity of symptoms in peptic ulcer disease (PUD), non-ulcer dyspepsia (NUD) and the irritable bowel syndroms (IBS). Dig Dis Sci 1986; 31 (Suppl.): 5, (Abstract.)
7. Glise H, Carling I, Hallerbäck B, et al. Treatment of peptic ulcers,Acid reduction or cytoprotection? Scand J Gastroenterol 1987; 22 (Suppl. 140): 39-17.
8. Bell NJV, Bailey RJ, Cohen L, et al. Treatment of acute duodenal and pyloric channel ulcers with sucralfate suspension (2 g/10 mL, twice daily): efficacy in smoking patients. Eur J Gastroenterol Hepatol 1993; 5: 287-91.
9. Laitinen S, Stahlberg M, Kairaluoma MI, et al. Sucralfate and alginate/antacid in reflux esophagitis. Scand J Gastroenterol 1985; 20: 229-32.
10. Matti I, Kairaluoma MD, et al. Sucralfate versus placebo in treatment of non-ulcer dyspepsia. Am J Med 1987; 83 (Suppl. 3B): 51-5.
11. Stahlberg M, Mokka R, Laitinen S, et al. Bile acid binding capacity of sucralfate, cholestyramine and antacids. Scand J Gastroenterol 1983; 18 (Suppl. 86): 86. (Abstract.)
12. Elsborg L, Beck B, Stubgaard M. Effect of sucralfate on gastroesophageal reflux in esophagitis. Hepatogastroenterology 1985; 32: 181-84.
13. Weiss W, Brunner H, Büttner GR, et al. Therapie der Refluxösophagitis mit Sucralfat. Dtsch Med Wochenschr 1983; 108: 1706-11.
14. Carling L, Cronstedt J, Engqvist A, et al. Sucralfate versus placebo in reflux esophagitis. A double-blind multicenter study. Scand J Gastroenterol 1988; 23: 1117-24.
15. Williams RM, Orlando RC, Bozymski EM, et al. Multicenter trial of sucralfate suspension for the treatment of reflux esophagitis. Am J Med 1987; 83 (Suppl. 3B): 61.
16. Müller P, Hotz J, Franz E, Simon B. Ranitidine in the treatment of non-ulcer dyspepsia. Arzneimittelforschung/Drug Res 1994; 10: 1130-2.
17. Pace F, Maconi G, Molteni M, Minguzzi M, Bianchi Porro G. Meta-analysis of the effect of placebo on the outcome of medically treated reflux esophagitis. Scand J Gastroenterol 1995; 30: 101-5.